RxDoctor Payments Data

Kent Braeutigam, DO

General Practice · Middleburg, FLNPI 1063437861

Payments from drug & device makers

$17,873in general payments, 2019–2025

Across 1,118 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$884
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$17,808100%
  • Education$60%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)176$2,365
AstraZeneca90$1,559
Amgen81$1,312
Novo Nordisk91$1,254
Lilly USA, LLC68$1,031
Boehringer Ingelheim60$884
Amarin Pharma, Inc.38$683
Sanofi-aventis U.S. LLC38$676
Pfizer49$646
Astellas Pharma US Inc26$532
Otsuka America Pharmaceutical, Inc.28$531
GSK27$417
Merck22$345
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$329
Takeda Pharmaceuticals U.S.A., Inc.14$271
Vanda Pharmaceuticals Inc.15$245
Bayer13$238
Antares Pharma, Inc.11$222
Abbott12$221
Novartis14$206
Idorsia Pharmaceuticals US Inc12$192
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)10$191
Medtronic(2 entities)5$187
Biohaven Pharmaceutical Holding Company Ltd.9$186
Kowa Pharmaceuticals America, Inc.11$185
Daiichi Sankyo Inc.11$183
Eisai Inc.11$163
Sunovion Pharmaceuticals Inc.10$152
Exact Sciences9$143
Lundbeck LLC7$142
Biohaven Pharmaceuticals, Inc.6$119
Biogen4$106
Axsome Therapeutics, Inc.4$95
Avanir Pharmaceuticals, Inc.6$93
Almatica Pharma LLC6$92
Orexo US, Inc.7$91
Dexcom, Inc.5$84
Johnson & Johnson6$81
Xeris Pharmaceuticals, Inc.4$80
Philips North America LLC3$76
Endo Pharmaceuticals Inc.6$74
Arbor Pharmaceuticals, Inc.5$74
Clarus Therapeutics Inc.6$69
Supernus Pharmaceuticals, Inc.4$68
Corcept Therapeutics4$67
IBSA Pharma Inc.4$66
Mannkind Corporation1$59
Jazz Pharmaceuticals Inc.3$56
Phathom Pharmaceuticals, Inc.2$44
E.r. Squibb & Sons, L.L.C.3$44
Esperion Therapeutics, Inc.2$43
Paratek Pharmaceuticals, Inc.3$43
Tolmar, Inc.3$41
Indivior Inc.2$40
Optinose US, Inc.2$39
Assertio Therapeutics, Inc.3$34
Corium, LLC2$31
Boston Scientific1$25
Noven Therapeutics, LLC1$25
Insulet Corporation1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,873 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$119,544
Medicare patients
386
Services billed
1,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$97,203
JardianceEmpagliflozin71$96,451
OzempicSemaglutide74$89,727
FarxigaDapagliflozin Propanediol52$42,376
MounjaroTirzepatide32$35,863
LinzessLinaclotide48$34,535
XareltoRivaroxaban26$27,537
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$20,189
UbrelvyUbrogepant12$14,014
MyrbetriqMirabegron18$13,502
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$12,600
ZenpepLipase/Protease/Amylase13$11,145
Tresiba Flextouch U-100Insulin Degludec11$10,130
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,113
Spiriva RespimatTiotropium Bromide11$9,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$884$106,22882 claims
PfizerEliquis$646$97,20390 claims
Novo NordiskOzempic$1,254$89,72774 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,559$61,951104 claims
AbbVieLinzess, Ubrelvy$2,365$48,54960 claims
Lilly USA, LLCMounjaro$1,031$35,86332 claims
GSKTrelegy Ellipta, Anoro Ellipta$417$32,78951 claims
Johnson & JohnsonXarelto$81$27,53726 claims
Astellas Pharma US IncMyrbetriq$532$13,50218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.

Other general practice in Middleburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →